The DOI matches its Crossref record.
The effect of anti‐CD40 ligand antibody on B cells in human systemic lupus erythematosus
Abstract
Objective: To determine the immunologic effects of anti–CD40 ligand (anti‐CD40L) therapy in 5 patients with systemic lupus erythematosus nephritis who participated in an open‐label study of a humanized anti‐CD40L monoclonal antibody. Methods: Serum and peripheral blood mononuclear cells were obtained before, during, and after treatment, and the frequency of Ig and anti‐DNA antibody–secreting B cells was analyzed by enzyme‐linked immunospot assay and by analysis of Epstein‐Barr virus (EBV)–transformed B cell lines. To determine the effect of treatment on somatic mutation of Ig genes, reverse transcriptase–polymerase chain reaction was performed on messenger RNA from 4 patients, using primers specific for the DP‐47 heavy chain gene and for IgG. Finally, B cell phenotype was investigated using flow cytometry. Results: Even a brief period of treatment with anti‐CD40L markedly reduced the frequency of IgG and IgG anti‐DNA antibody–producing B cells, and these changes persisted for several months after cessation of treatment. To confirm these findings, EBV‐transformed B cell lines were screened from each of 3 patients, and a 10‐fold decrease in anti‐DNA antibody–secreting cell lines was found after treatment in all 3 patients. Few differences in mutation patterns were observed before and after treatment; however, the frequency of germline‐encoded DP‐47 sequences was significantly increased before treatment and normalized following treatment. Flow cytometric analysis of B cells revealed expansion of a CD27−/IgD− B cell subset in some of the patients, which did not change with treatment. Conclusion: These are the first mechanistic studies of the effect of anti‐CD40L therapy in human autoimmune disease. The results suggest that further studies of CD40L blockade are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Boumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & on behalf of the BG9588 Lupus Nephritis Trial Group (2003) · Arthritis & Rheumatism · doi:10.1002/art.10856 · Cited by 618
Self-citationWei, C., Anolik, J., Cappione, A., Zheng, B., Pugh-Bernard, A., Brooks, J., Lee, E.-H., Milner, E. C. B., & Sanz, I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6624 · Cited by 604
Dysregulation of germinal centres in autoimmune disease
Vinuesa, C. G., Sanz, I., & Cook, M. C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2637 · Cited by 464
Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond
Karnell, J. L., Rieder, S. A., Ettinger, R., & Kolbeck, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.005 · Cited by 334
Metadata
- Authors
- Huang, W., Sinha, J., Newman, J., Reddy, B., Budhai, L., Furie, R., Vaishnaw, A., & Davidson, A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2002-06
- Volume
- 46
- Issue
- 6
- Pages
- 1554-1562
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2057338076
- Cited by
- 165
- References
- 0
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of anti‐CD40 ligand antibody on B cells in human systemic lupus erythematosus. https://app.cochat.ai/papers/10.1002/art.10273
- The paper
- Huang, W., Sinha, J., Newman, J., Reddy, B., Budhai, L., Furie, R., Vaishnaw, A., & Davidson, A. (2002). The effect of anti‐CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis & Rheumatism. https://doi.org/10.1002/art.10273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.